Literature DB >> 8710739

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

U Wetterich1, H Spahn-Langguth, E Mutschler, B Terhaag, W Rösch, P Langguth.   

Abstract

PURPOSE: To evaluate carrier-mediated intestinal secretion of talinolol enantiomers in vivo and in vitro.
METHODS: In clinical studies with i.v. and p.o. dosage of rac-talinolol (30 mg and 100 mg, resp.) performed in a small number of cholecystectomized patients total and partial clearances were determined on the basis of plasma, bile and urine concentrations. The dose-dependence of AUC was investigated in 12 healthy volunteers (25, 50, 100, and 400 mg rac-talinolol as single p.o. doses). Concentration-dependence of the permeability across Caco-2 cell monolayers included concentrations from 0.1 to 2.0 mM, inhibition by verapamil was tested at 0.5 mM.
RESULTS: The total clearance as well as the apparent oral clearance (CL/F) were slightly higher for S-(-)- than for R-(+)-talinolol. Calculation of the partial clearances showed that also the residual clearance was higher for the S- than for the R-enantiomer. In the healthy volunteers, CL/F increased with increasing doses, while the S/R ratio decreased approaching unity for the highest dose. Also the results from Caco-2 cell permeation studies yielded a clear concentration-dependence with decreasing stereoselectivity for the higher concentration range. Permeability of both enantiomers was considerably higher for b-->a than a-->b transport, however, this difference disappeared when verapamil was added.
CONCLUSIONS: Although not very expressed, the detected stereoselectivities indicate a preferential absorption of R-(+)-talinolol in a lower concentration and dose range, which is most probably due to a moderate stereoselectivity at the carrier system involved in intestinal secretion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710739     DOI: 10.1023/a:1016029601311

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

2.  Dose-dependency in the exsorption of theophylline and the intestinal dialysis of theophylline by oral activated charcoal in rats.

Authors:  K Arimori; M Nakano
Journal:  J Pharm Pharmacol       Date:  1988-02       Impact factor: 3.765

3.  Intestinal absorption of a beta-adrenergic blocking agent nadolol. I. Comparison of absorption behavior of nadolol with those of other beta-blocking agents in rats.

Authors:  T Yamaguchi; C Ikeda; Y Sekine
Journal:  Chem Pharm Bull (Tokyo)       Date:  1986-08       Impact factor: 1.645

4.  Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport.

Authors:  P F Augustijns; T P Bradshaw; L S Gan; R W Hendren; D R Thakker
Journal:  Biochem Biophys Res Commun       Date:  1993-12-15       Impact factor: 3.575

5.  Pharmacokinetics of morphine and its surrogates. XI: Effect of simultaneously administered naltrexone and morphine on the pharmacokinetics and pharmacodynamics of each in the dog.

Authors:  P Langguth; P J Khan; E R Garrett
Journal:  Biopharm Drug Dispos       Date:  1990-07       Impact factor: 1.627

6.  Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators.

Authors:  J Hunter; M A Jepson; T Tsuruo; N L Simmons; B H Hirst
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

7.  Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

8.  The contribution of intestinal secretion to the dose-dependent absorption of celiprolol.

Authors:  S M Kuo; B R Whitby; P Artursson; J A Ziemniak
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

Review 9.  Clinical trials of agents that reverse multidrug resistance. A literature review.

Authors:  M Raderer; W Scheithauer
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

10.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

Authors:  P Artursson
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

View more
  21 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate.

Authors:  Jack G Shi; Yan Zhang; Swamy Yeleswaram
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 3.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.

Authors:  R Mehvar; F Jamali
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

5.  In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.

Authors:  Marija Tubic; Daniel Wagner; Hilde Spahn-Langguth; Michael B Bolger; Peter Langguth
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 6.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

7.  Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter.

Authors:  S Döppenschmitt; H Spahn-Langguth; C G Regårdh; P Langguth
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

8.  Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

9.  Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

10.  Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

Authors:  Annika Bernsdorf; Thomas Giessmann; Christiane Modess; Danilo Wegner; Stefanie Igelbrink; Ute Hecker; Sierk Haenisch; Ingolf Cascorbi; Bernd Terhaag; Werner Siegmund
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.